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Abstract
Objectives: Primary Adrenocortical insufficiency
(Addison’s disease) is a potentially fatal condition that
often develops incidentally and can be easily over-
looked. Although rare in the general population, it is
more common in patients with type 1 diabetes mellitus
(T1D). In this study, we reviewed our experience with
the occurrence of associated adrenal insufficiency (AI)
in children with T1D over 15 year’s period at King
Khalid University Hospital (KKUH), Riyadh, Saudi
Arabia
Methods: This is a retrospective hospital based study,
included children and adolescents with T1D at KKUH in
the period January 1995eDecember 2012. All patients
were serologically screened for Celiac and thyroid dis-
eases. Adrenal function was assessed at the time of
diagnosis, and annually thereafter by measuring serum
cortisol and adrenal corticotrophic hormone (ACTH)
using the available commercial kit. Adrenal cortex anti-
bodies (AAA) test was done by Bioscientia laboratory,
Germany, in one patient.
A.M.I. Babiker et al. 225Results: In a cohort of 305 children and adolescents with
T1D at KKUH, only one patient was found to have AI as
a part of autoimmune polyendocrine syndrome type 1.
Thyroid functions were abnormal in 65 (21.3%) patients.
Of these, 26 (8.5%) patients have evidence of overt hy-
pothyroidism and 39 (12.8%) patients had subclinical
hypothyroidism. In twenty-six patients (8.5%), the in-
testinal biopsy results were positive for CD.
Conclusion: There is no international consensus on the
issue of screening for AI in children with T1D. In our
experience, we do not favour screening for AI in children
with T1D unless there is a clear risk factor.
Keywords: Addison’s disease; Adrenocortical insufficiency;
Autoimmune; Diabetes; Screening
 2014 Taibah University. Production and hosting by
Elsevier Ltd. All rights reserved.Introduction
Type 1 Diabetes Mellitus (T1D) is the most common
endocrinopathy to have clinical onset in childhood and
adolescence with varied pathogenesis, clinical appearance and
outcome and seriously affect patients and families life. A
combination of genetic, environmental and immunological
factors exerts to a T cell mediated autoimmune process tar-
geted against the insulin producing beta cells in the pancreatic
IslandofLangerhans.1The incidence is increasingworldwide.2
Patients affected by T1D are at increased risk of devel-
oping other autoimmune conditions like Coeliac Disease
(CD), autoimmune thyroid disorders (ATD) and AI. The
national institute of clinical excellence guidance (NICE) and
the American Diabetes association (ADA) included recom-
mendations about the screening for ATD and CD in children
with T1D but there was no guidance regarding screening for
AI.3,4 The issue of screening for AI in T1D is still
controversial.5e8 While Triolo et al. and Brewer et al.
recommended screening, Babiker et al. and Mark et al. do
not favour screening for autoimmune AD and feels that
Adrenal antibodies should be requested in children with
T1D only when AI is clinically suspected.6e8
This article reviewedour experienceovermore than15years
with children and adolescents with T1D in a cohort of 305
patients at the paediatric diabetes clinic at King Khalid Uni-
versityHospital,King SaudUniversity, Riyadh, SaudiArabia.
Materials and Methods
This is a retrospective hospital based study, included
children and adolescents who were diagnosed and followed
for T1D, at the paediatric diabetes clinic at King Khalid
University hospital (KKUH), Riyadh, Saudi Arabia in the
period January 1995eDecember 2012. The diagnosis of T1D
was based on history of polyurea, polydipsia and weight loss,
with an elevated random blood sugar of >11.2 mmol/L.
Subjects were serologically screened for other associated
autoimmune diseases, at the time of diagnosis and annuallythereafter. Serologically screening test for CD includes anti-
glidin antibody (AGA), Anti-endomyseal antibodies (EMA)
and anti-tissue transglutaminase (Ttg) antibody. Serological
tests are fully automated, except EMA test which is time
consuming and operator dependant. For serological tests,
immunoglobulin A was also measured. In case of a positivity
of one or more of these tests, the patient is referred for upper
endoscopy where multiple biopsy specimens were taken. The
severity of small bowel mucosal damage was reviewed by an
experienced gastrointestinal pathologist and graded accord-
ing to the Marsh classification from 1 to III. The diagnosis of
CD is based on the revised criteria for the diagnosis of CD.
Patients were screened for the thyroid dysfunction by
thyroid stimulating hormone (TSH) and free thyroxin (FT4)
at the time of diagnosis, and annually thereafter. These were
made by methods using commercially available kits. The
quality control of the assay was monitored by the Middle
East Extended Quality Assessment Scheme (MEEQAS) in
Riyadh. Anti-thyroid microsomal and thyroglobulin anti-
bodies were estimated using haemagglutination method, and
a titre of 1:100 or more was considered positive. Diagnosis of
subclinical autoimmune thyroiditis was based on high levels
of TSH or more than 5 IU/L associated with normal FT4,
while clinical hypothyroidism (overt hypothyroidism) was
associated with low FT4 levels and/or goitre.
Adrenal function was assessed at the time of diagnosis,
and annually thereafter by measuring serum cortisol and
adrenal corticotrophic hormone (ACTH) using the available
commercial kit. Adrenal cortex antibodies (ACA) test was
done by Bioscientia laboratory, Germany, in one patient.
The study was approved by institutional Review Board
(Ethical and Research Committee) of the College of Medi-
cine of King Saud University (KSU), Riyadh, Saudi Arabia.Results
All patients were serologically screened for CD; sixty-two
patients (20.3%) were subsequently referred to paediatric
gastroenterologist to perform upper gastrointestinal endos-
copy and biopsy when the patient has one or two positive
screening tests.
In twenty-six patients (8.5%) (n ¼ 17 females, n ¼ 9
males), the biopsy results were positive for CD with a mean
of 5 years duration after the diagnosis of T1D. Their age
range was between seven and sixteen years (mean 11.5) and
the duration of T1D was 1.5e11.5 years (mean 5 years). The
other 36 patients (11.8%) had normal biopsies and therefore,
considered to have potential CD.
Thyroid functions were abnormal in 65 (21.3%) patients
with a mean of 2.5 years duration after the diagnosis with
T1D in 61 patients, while four patients were diagnosed with
hypothyroidism before T1D. Of these 65 patients, 26 (8.5%,
n ¼ 26 patients) have evidence of overt hypothyroidism, i.e.
high TSH and low FT4 and (12.8%, n ¼ 39 patients) had
subclinical hypothyroidism, i.e. TSH of more than 5 IU/L
and normal free T4. Thyroid microsomal peroxidise (TPO)
and thyroglobulin (TG) antibodies were done in the sera of
114 (37.4%) patients. Seventy-six (66.7%), were euthyroid,
twenty (17.5%) patients were having overt hypothyroidism,
while only eighteen (15.8%) patients had subclinical hypo-
thyroidism. Interestingly, in sixteen (80%) patients with
Screening for autoimmune diseases226overt hypothyroidism both TPO and TtG antibodies were
positive, while in the majority of euthyroid patients (93.2%)
both TPO and TtG antibodies were negative.
Of all patients, a 9 years girl presented with adrenal
insufficiency with low serum cortisol and high adreno-
corticotrophine (ACTH) 195 pg/ml (N ¼ 10e55 pg/ml).
The ACA was 6.8 mcg/dl (N ¼ 10e25 mcg/dl) and the
diagnosis was confirmed by a flat cortisol response in a
short synacthin test. Serum rennin and aldosteron levels
were not done. The patient also developed hypoparathy-
roidism and chronic candidiasis, therefore a diagnosis of
autoimmune polyendocrinopathy candidiasis ectodermal
dystrophy (APECED), APS type 1, with a positive AIRE
gene mutation, was made. Six months later, she developed
T1D and found to be hypothyroid, also with positive TPO
and TtG antibody. She was diagnosed with CD based on
small bowel biopsy, a year later. She died at 14 years of
age because of worsening of her autoimmune hepatitis
which she also developed eventually. She had other three
siblings with the same syndrome. Otherwise none of the
patients had signs or symptoms or biochemical evidence of
adrenal insufficiency prior to or after the diagnosis of
T1D.Discussion
Patients with T1D have increased risk of other organ
specific autoimmune disorders including ATD, CD, and AI
(Addison’s disease).9e12 Addison’s disease is a potentially life
threatening condition caused by an immune mediated
destruction of the adrenal cortex. The combination of
Addison’s disease with T1D and/or ATD is known as
autoimmune polyendocrine syndrome type 2 (APS-2). T1D
commonly precedes the development of AI in most patients
with APS-2.13e15 It is a rare disease and usually presents
with non-specific symptoms, the diagnosis can be easily
overlooked and require a high degree of clinical suspicion.
After the appearance of antibodies to the adrenal cortex
and/or 21 hydoxylase, the first evidence of AI is usually
increased in plasma rennin activity, with a low normal or
low serum aldosteron concentration, reflecting salt loss
because of failing zona glomerulosa. Several months to
years later, zona fasiculata dysfunction becomes evident
initially by a raised serum ACTH level followed by a
decreasing serum cortisol response to ACTH stimulation,
and finally by a decreasing basal serum cortisol
concentration, and the appearance of symptoms.16
Addison’s disease is relatively rare (0.01%) in general
population. However, the prevalence is reported to be high
among patients with T1D (0.8e1.2%). The prevalence of
adrenal autoantibodies is even higher (1.3e2.3%). The risk
of adrenal autoimmunity and Addison’s disease in T1D is
even greater when anti-thyroid autoimmunity is detected.16
Adrenal autoantibodies may be useful markers for the
prediction of progression to Addison’s disease in children
with higher predictive values than adults. Antibodies can be
measured against several steroidogenic enzymes (21 hydox-
ylase) and adrenal cortex autoantibodies (ACA). They are
present in the serum of more than 90% of patients with
autoimmune Addison’s disease, although negative anti-
bodies do not rule out autoimmune AI. ACA positivechildren have been reported to have a higher rate of pro-
gression to overt Addison’s disease. This suggests the
importance of screening.17e20
The development of adrenal insufficiency in patients with
T1D should be suspected in any patient presenting with
unexplained hypoglycaemia or reduced insulin
requirements.20
Autoimmune diseases are usually preceded by a long
preclinical phase before becoming overt.21 This phase can be
identified by the presence of autoimmune antibodies as
markers of disease progress. Such identification might
allow immunological treatment, in some cases, whereby
disease is prevented.21 Alternatively, perhaps life-
threatening, yet treatable conditions, such as AI could be
avoided.21 Further work is needed, for most of autoimmune
associated diseases, to assess the natural history of disease
progression and predictive value of autoimmune antibodies
testing in healthy individuals.
Conclusion
As yet, there is no international consensus on screening
for AI in children and adolescents with T1D. In our experi-
ence, there is very low incidence of AI during routine
assessment of children with T1D compared with much higher
incidence of CD and ATD.
Recommendations and limitations
We do not favour routine screening for AI in children
with T1D unless there is a clear risk factor in the history and
clinical examination. However, extended follow-up for this
cohort of patients will be important to determine the natural
history of the development of AI. This study is limited
because it only utilises serum cortisol and ACTH to screen
for AI. ACAwas only performed in the APS-1 patient who in
fact was diagnosed with AI prior to T1D.
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